BRKR News & Events

PreOmics and Biognosys announced a favorable outcome in an inter partes review proceeding IPR2024-01473 before the U.S. Patent Trial and Appeal Board. The PTAB has revoked the central claims of U.S. Patent No. 11,435,360, which is owned by The Brigham and Women's Hospital, and exclusively licensed to Seer, Inc. The USPTO struck down the sole independent claim of the '360 patent, among other claims. The PTAB specifically invalidated Claim 1, which attempted to cover workflows using multiple nanoparticle types to form biomolecule coronas and detect proteins across a wide dynamic range. "This outcome confirms what we have consistently believed from the outset: the fundamental concepts at issue were already known in the scientific literature," said Dr. Oliver Rinner, co-founder and managing director of Biognosys. "We welcome the PTAB's thorough evaluation and we are very pleased with this clear result."

Seer (SEER) announced that the Patent Trial and Appeal Board, or PTAB, of the U.S. Patent and Trademark Office issued a Final Written Decision on March 23 in an inter partes review of U.S. Patent No. 11,435,360 B2. The inter partes review was filed by PreOmics and Biognosys, each a subsidiary of Bruker (BRKR), challenging 11 of 29 claims of the '360 Patent. The '360 patent covers methods for analyzing biological samples using engineered nano- and microparticles that form protein coronas, resulting in protein enrichment that underlies Seer's Proteograph platform for deep proteomic analysis. The '360 Patent is owned by The Brigham and Women's Hospital, Inc. and is exclusively licensed to Seer. A total of 23 claims, including five challenged claims and 18 unchallenged claims, remain valid and protect Seer's nanoparticle protein enrichment technology for analyzing biological samples, including cells, tissues and biofluids. The upheld claims are directed to detecting proteins across a wide concentration range and to particle-related aspects of Seer's technology, both of which enable deep proteomic analysis.